| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gtbl.in | |
| Market Cap | 1,034.44 Cr. | |
| Enterprise Value(EV) | 1,013.72 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 36.74 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 19.38 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 92.19 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 7.72 | Calculated using Price: 712.00 |
| Dividend Yield | 1.54 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.45 Cr. | 14,528,702 Shares |
| FaceValue | 5 | |
| Company Profile | ||
| Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised facility for all products.The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States. | ||
| 1 Day |
|
+1.02% |
| 1 Week |
|
-5.97% |
| 1 Month |
|
-7.73% |
| 3 Month |
|
-4.06% |
| 6 Month |
|
+34.40% |
| 1 Year |
|
+60.18% |
| 2 Year |
|
+200.82% |
| 5 Year |
|
+1275.72% |
| 10 Year |
|
+6108.70% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 302.71 | 72.63 | 38.06 | 41.85 | 77.99 | 53.82 | 50.35 | |||
| Return on Capital Employed (%) | 209.07 | 113.74 | 80.38 | 54.67 | 42.22 | 44.88 | 85.96 | 67.89 | 67.91 | |
| Return on Assets (%) | 26.54 | 29.88 | 31.50 | 24.25 | 18.45 | 24.07 | 45.62 | 35.65 | 37.08 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | -5 | -1 | 4 | 8 | 12 | 19 | 42 | 70 | 103 | 134 | |
| Non Curr. Liab. | 6 | 6 | 2 | 1 | 0 | 1 | 5 | 2 | 2 | 2 | |
| Curr. Liab. | 15 | 10 | 9 | 12 | 8 | 13 | 24 | 26 | 32 | 25 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 16 | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 161 | |
| Non Curr. Assets | 13 | 11 | 11 | 13 | 13 | 25 | 35 | 25 | 44 | 53 | |
| Curr. Assets | 3 | 3 | 3 | 8 | 8 | 8 | 36 | 73 | 93 | 107 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 16 | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 161 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 30 | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 140 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 | |
| Total Income | 30 | 32 | 33 | 36 | 39 | 43 | 87 | 94 | 119 | 145 | |
| Total Expenditure | -24 | -25 | -27 | -30 | -33 | -34 | -53 | -50 | -57 | -70 | |
| PBIDT | 7 | 6 | 6 | 6 | 6 | 10 | 34 | 44 | 62 | 75 | |
| Interest | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | |
| Taxation | -1 | -1 | -2 | -8 | -11 | -15 | -19 | ||||
| Exceptional Items | |||||||||||
| PAT | 5 | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 53 | |
| Adjusted EPS | 3 | 3 | 3 | 3 | 3 | 4 | 16 | 21 | 30 | 37 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 4 | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | |
| Cash Fr. Inv. | -3 | 0 | 0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | |
| Cash Fr. Finan. | 2 | -3 | -3 | -3 | 0 | -4 | 5 | 2 | -5 | -14 | |
| Net Change | 0 | 1 | -1 | 0 | 0 | 1 | 0 | 0 | 3 | -4 | |
| Cash & Cash Eqvt | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 |
|
Fri, 27 Jan 2023
Board Meeting Intimation for Inter Alia To Consider The Un-Audited Standalone Financial Results For The Quarter And Nine Months Ended On 31St December 2022. GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Friday 03rd February 2023 inter alia to consider the Un-audited Standalone Financial Results for the Quarter and nine months ended on 31st December 2022.Further in continuation of our Letter dated 26th December 2022 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Sunday 1st January 2023 which shall remain closed till the closure of trading hours on 05th February 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code") adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. |
|
Tue, 17 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation 2015 we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received below mentioned intimation / request(s) for Loss of Share Certificate(s) / issuance of duplicate share certificate(s) from the following shareholder(s):Sr. No. Name Folio No. Cert. No. Number of Shares Dist. No.From Dist. No.To1 RUMIE JAMSHED GAZDAR R001994 12114 50 2064801 2064850 2 RUMIE JAMSHED GAZDAR R001994 1498 50 1534001 1534050 We shall issue the duplicate Share Certificate(s) only after the necessary formalities are carried out by the Shareholder(s). |
|
Tue, 17 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation 2015 we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received below mentioned intimation / request(s) for Loss of Share Certificate(s) / issuance of duplicate share certificate(s) from the following shareholder(s):Sr. No. Name Folio No. Cert. No. Number of Shares Dist. No.From Dist. No.To1 RATILAL U MEWADA R002030 16846 50 2301401 2301450 2 RATILAL U MEWADA R002030 16846 50 2301401 2301450 3 RATILAL U MEWADA R002030 16849 50 2301551 2301600 4 RATILAL U MEWADA R002030 16849 50 2301551 2301600 We shall issue the duplicate Share Certificate(s) only after the necessary formalities are carried out by the Shareholder(s). |
| Mon, 30 Jan 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors